BLBryan Cho-Wing Li

Bryan Cho-Wing Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bryan Cho-Wing Li has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study

    by Jeffrey Sum-Lung Wong, Yawen Dong, Vikki Tang, Thomas Leung, Cynthia S. Y. Yeung, Anna Tai, Ada Law, Tracy Shum, Gerry Gin-Wai Kwok, Bryan Cho-Wing Li, et al.

    (1) Background: Cabozantinib is approved in sorafenib-exposed advanced hepatocellular carcinoma (aHCC). We evaluated the real-life pattern of use, efficacy, and tolerability of cabozantinib in aHCC. (2) Methods: This territory-wide study included consecutive aHCC patients who received cabozantinib between February 2018 and September 2020 in Hong Kong. The objective response rate (ORR), disease control rate (DCR), overall survival (OS), and adverse events (AE) were assessed. (3) Results: Overall, 42 patients were included. Approximately 83.3% had Child-Pugh A cirrhosis. About 64.3% received cabozantinib as a single agent, and the remaining 35.7% received cabozantinib as an add-on to immune checkpoint inhibitors (ICIs). For single-agent patients, the median follow-up was 6.7 months. The ORR was 3.7%, DCR was 44.4%, and the median OS was 8.28 months. About 74.1% of patients experienced any AEs with 7.4% having grade ≥3 AEs. Among patients who received prior ICIs (n = 16), the ORR was 6.3%, and the median OS was 8.28 months. An exploratory analysis of patients who received cabozantinib as an add-on to ICIs showed an ORR of 6.7% and a median OS of 15.1 months, with 73.3% having any AE and 13.3% having grade ≥3 AEs. (4) Conclusions: Cabozantinib had good anti-tumor activity, survival benefits, and acceptable tolerability in real-life aHCC patients.


  • Embracing the setting sun: provision of palliative care via a collaborative model between hospital and community for patients with intellectual disabilities

    by Cho Wing Li, Yuk Chun Wong, Yiu Man Lo, Mau Kwong Sham, Hon Wai Cheng, Theresa Lai, Wai Kee Lau, Kwok Ying Chan

    Palliative care (PC) evolved from taking care of terminal cancer patients to modern concept of early integration into disease trajectories of patients with life limiting cancer and non-cancer diseases (1).